CHAI

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Retrieved on: 
星期四, 五月 30, 2024
Technology, Health Technology, Software, Other Health, Biotechnology, Health, Science, Oncology, Artificial Intelligence, Other Science, Uncertainty, Patient, Doctor of Philosophy, General partnership, American Urological Association, AUA, Bladder cancer, H&E, Neoplasm, Disease, Histology, Publication, AI, Cancer, Biomarker, Pear VC, Labs, Valar in Middle-earth, BCG, Abstract, CHAI, Physician, Annual general meeting

Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.

Key Points: 
  • Valar Labs , the developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, announced a $22 million Series A financing.
  • The funding follows Valar Labs’ completion of a recent international, multi-institution validation study and subsequent launch of Vesta, the first AI-based diagnostic test to predict response to first line treatment in bladder cancer.
  • And bladder cancer is only the beginning; we can’t wait to see where they take the technology next.”
    Valar Labs was founded to reduce uncertainty in cancer treatment decisions.
  • “Valar Labs could transform how we approach cancer treatment decisions for a large number of patients today,” said Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.

Resource-Appropriate Cancer Care, Including Coexisting Health Issues of HIV and Cancer, to be Addressed During Meeting in Nairobi

Retrieved on: 
星期三, 五月 1, 2024
Cancer, NCCN, AIDS, ACC, Safety, American Cancer Society, Uganda Cancer Institute, HIV/AIDS, ACS, CHAI, Senior, Clinton Foundation, Patient, MPH, Drug, HIV, MBA, Kaposi's sarcoma, Non-Hodgkin lymphoma, Dietary supplement

NAIROBI, Kenya, May 1, 2024 /PRNewswire/ -- Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer—a collaboration between the National Comprehensive Cancer Network® (NCCN®), African Cancer Coalition (ACC), American Cancer Society (ACS), and Clinton Health Access Initiative (CHAI). The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics. The event runs from May 1-3, 2024.

Key Points: 
  • The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics.
  • "Many cancers occur more frequently in people with HIV and AIDS, including AIDS-defining cancers like non-Hodgkin lymphoma, Kaposi sarcoma, and invasive cervical cancer.
  • The NCCN Harmonized Guidelines™ employ color-coded recommendations to delineate the best possible cancer care across various settings and resource availability.
  • The Nairobi meeting will focus on updates to the NCCN Harmonized Guidelines™ for People Living with HIV, as well as the following cancer types:

Resource-Appropriate Cancer Care, Including Coexisting Health Issues of HIV and Cancer, to be Addressed During Meeting in Nairobi

Retrieved on: 
星期三, 五月 1, 2024
Cancer, NCCN, AIDS, ACC, Safety, American Cancer Society, Uganda Cancer Institute, HIV/AIDS, ACS, CHAI, Senior, Clinton Foundation, Patient, MPH, Drug, HIV, MBA, Kaposi's sarcoma, Non-Hodgkin lymphoma, Dietary supplement

NAIROBI, Kenya, May 1, 2024 /PRNewswire/ -- Local and global experts are meeting in Nairobi, Kenya to update clinical practice guidelines as part of ongoing work with Allied Against Cancer—a collaboration between the National Comprehensive Cancer Network® (NCCN®), African Cancer Coalition (ACC), American Cancer Society (ACS), and Clinton Health Access Initiative (CHAI). The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics. The event runs from May 1-3, 2024.

Key Points: 
  • The meeting brings together subject matter experts to update NCCN Harmonized Guidelines™ for Sub-Saharan Africa, featuring updates for treating cancer in people with HIV and other important topics.
  • "Many cancers occur more frequently in people with HIV and AIDS, including AIDS-defining cancers like non-Hodgkin lymphoma, Kaposi sarcoma, and invasive cervical cancer.
  • The NCCN Harmonized Guidelines™ employ color-coded recommendations to delineate the best possible cancer care across various settings and resource availability.
  • The Nairobi meeting will focus on updates to the NCCN Harmonized Guidelines™ for People Living with HIV, as well as the following cancer types:

Valar Labs Announces Validation of First Histology-based Test to Predict Response to BCG in Bladder Cancer

Retrieved on: 
星期三, 五月 1, 2024
Health, Technology, Health Technology, Artificial Intelligence, Oncology, Jane, Risk, American Urological Association, Recurrence, BCG, Docetaxel, CHAI, Data, University, Patient, Histology, Physician, AUA, Multimedia, Toxicity, Biomarker, Neoplasm, Associate, Medicine, Bladder cancer, Labs, Medical imaging

The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.

Key Points: 
  • The biomarkers were successfully validated across 1000+ patients and 12 centers on four end-points, making it the largest validation study of its kind in bladder cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240501832149/en/
    The CHAI biomarkers offer independent prognostic capabilities for high-grade recurrence and muscle-invasive progression in bladder cancer.
  • Validated across more than 1,000 patients and 12 centers, these biomarkers, available through the Vesta test, can enhance first-line treatment decision-making for non-muscle invasive bladder cancer.
  • We are able to visualize these biomarkers and gain a better understanding of how tumor morphology correlates to treatment response.”

ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections

Retrieved on: 
星期四, 四月 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Stenotrophomonas maltophilia, Mortality, Genetically modified bacteria, Cefiderocol, Safety, Kidney disease, Infection, Survival, Immunosuppression, Diabetes, Pseudomonas aeruginosa, ECCMID, Head, Urinary tract infection, CHAI, Patient, Hospice and palliative medicine, Gram-negative bacteria, Klebsiella pneumoniae, Chronic obstructive pulmonary disease, Pharmaceutical industry

Please see below under About Cefiderocol for full indications of Fetroja in the U.S.

Key Points: 
  • Please see below under About Cefiderocol for full indications of Fetroja in the U.S.
  • Additionally,19.5% of patients had polymicrobial infections.1
    The study included 261 critically ill adult patients with limited treatment options who received cefiderocol for less than 28 days as part of Shionogi’s Early Access Program in Spain.
  • Real-world evidence is particularly important when reviewing antibiotic use for multidrug-resistant pathogens because of the challenges of conducting randomized clinical trials.
  • We also know how important it is to ensure equitable, global, access to essential medicines like cefiderocol.

Butterfly Network, Clinton Health Access Initiative, and Global Ultrasound Institute Partner to Advance Maternal and Fetal Health in South Africa

Retrieved on: 
星期一, 四月 15, 2024
Technology, Medical Devices, Semiconductor, Hospitals, Health Technology, Software, Training, General Health, Health, Education, Melon, Mortality, Organization, Public sector, Patient, GUSI, Health equity, Pregnancy, Woman, Core Group, Health care, Partnership, Entrepreneurship, Disease, CHAI, Clinton Foundation, Global Health, Bill, Mother, Multimedia, JAMF, Stillbirth, Butterfly network, Network, Global health, Nursing

As of today, the organizations have initiated Phase Two of Butterfly's 1,000 iQ+ probe deployment and point-of-care ultrasound training program for maternal and fetal health in Sub-Saharan Africa.

Key Points: 
  • As of today, the organizations have initiated Phase Two of Butterfly's 1,000 iQ+ probe deployment and point-of-care ultrasound training program for maternal and fetal health in Sub-Saharan Africa.
  • View the full release here: https://www.businesswire.com/news/home/20240415955318/en/
    Healthcare workers in Eastern Cape, South Africa enrolled in a week-long Butterfly point-of-care ultrasound training program.
  • "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa.
  • We look forward to working closely with Butterfly Network and the Global Ultrasound Institute to achieve our shared goal of advancing global health equity."

New consortium of healthcare leaders announces formation of Trustworthy & Responsible AI Network (TRAIN), making safe and fair AI accessible to every healthcare organization

Retrieved on: 
星期一, 三月 11, 2024
Informatics, Algorithm, Responsibility, Information technology, Health, Biomedical Research, Patient, Cleveland Clinic, Approximation error, Artificial intelligence in healthcare, Microsoft, Public, AdventHealth, Mass General Brigham, Coalition, Science, Policy, Safety, Boston Children's Hospital, VUMC, Organization, Bias, Trust (social science), Research, AI, University, Nouvelle AI, MPH, Vanderbilt University Medical Center, Hospital, Sharp HealthCare, Internal medicine, Health informatics, Conference, Public health, Cardiology, Caregiver, MedStar Health, CHAI, HIMSS, Mount Sinai Health System, Medical device

New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.

Key Points: 
  • New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs.
  • Enabling registration of AI used for clinical care or clinical operations through a secure online portal.
  • "By working together, TRAIN members aim to establish best practices for operationalizing responsible AI, helping improve patient outcomes and safety while fostering trust in healthcare AI."
  • "We are excited to join our TRAIN partners in the journey to accelerate AI innovation in an ethical, responsible and safe way."

COALITION FOR HEALTH AI (CHAI) NAMES BOARD OF DIRECTORS AND CEO

Retrieved on: 
星期一, 三月 4, 2024
Disability, CHAI, Generative, Government, NHC, Health care, Human, MITRE, Organization, Policy, Duke, Algorithm, Coalition, Forecasting, Food and Drug Administration, Ecosystem, HL7, Machine learning, MBBS, Carnegie Mellon University, Partnership, Chairperson, National Health Council, Learning, Technology policy, Safety, MPH, Conditional sentence, Commissioner, Research, Human services, Stanford University Medical Center, MPP, Workgroup, AI, FDA, Food, Veterans Health Administration, National academy, Artificial intelligence in healthcare, Communication, Doctor of Philosophy, Medicare, Patient, Duke University, Biostatistics, Medicine, Privacy, Publication, Medical device

WASHINGTON, March 4, 2024 /PRNewswire/ -- Today CHAI, the Coalition for Health AI, announced Dr. Brian S. Anderson, a CHAI co-founder and chief digital health physician at MITRE, to be its first CEO. It also named members of CHAI's inaugural Board of Directors chaired by Dr. John Halamka, a CHAI co-founder and the president of Mayo Clinic Platform, as well as leaders of key advisory boards. CHAI includes representatives from over 1300 member organizations including hospital systems, tech, government agencies and advocacy groups. The board also opened general membership for individuals and organizations and formalized the process for joining and contributing to CHAI work groups.

Key Points: 
  • CHAI today also announced partnerships with the patient advocacy group, the National Health Council, and health standards organization, HL7.
  • To implement this commitment, CHAI established a governance structure extending beyond the Board of Directors to include a small number of strategically defined advisory boards.
  • I am excited to be a part of the Coalition for Health AI to help create a future where responsible AI practices are the cornerstone."
  • – Michael Pencina, board member
    "Decades of research have brought us to a transformative moment for AI and the applications in medicine are unbounded.

John Snow Labs is All In on Generative AI, Achieving 82M Spark NLP Downloads, 5x NLP Lab Growth, and New State-of-the-Art LLM Accuracy Benchmarks

Retrieved on: 
星期二, 一月 23, 2024
ONNX, Classification, Report, Veterans' affairs, Privacy, Research, NLP, RAG, Coalition, OpenAI, AI, Bias, Oracle, GPT, Publishing, AWS, Medicine, Accenture, Hugging Face, CHAI, Organization, News, Azure, LLM, Medical device

The shift across John Snow Labs’ product suite has resulted in several notable company milestones over the past year including:

Key Points: 
  • The shift across John Snow Labs’ product suite has resulted in several notable company milestones over the past year including:
    82 million downloads of the open-source Spark NLP library.
  • John Snow Labs has won the 2024 Global 100 Award for the Best Medical Application of LLMs.
  • Additionally, John Snow Labs has developed a series of new integrations with partners to enable customers to build end-to-end solutions faster.
  • John Snow Labs now has 26 partners including Oracle, AWS, Azure, Deloitte, Carahsoft, Accenture, and Booz Allen Hamilton.

USAID Taps CHAI, GETF to Launch Coalition That Will Test Innovative Approaches to Address Antimicrobial Resistance in Low- and Middle-Income Countries

Retrieved on: 
星期五, 一月 12, 2024
Philanthropy, Health, Other Philanthropy, Other Health, Foundation, General Health, Pharmaceutical, Dependent and independent variables, USAID, Infection, International development, Therapy, CHAI, AMR, Medical device

The new coalition, the Antimicrobial Resistance Access and Stewardship Initiative (AMRASI), is a groundbreaking initiative that will use a sustainable, market-driven approach to address critical gaps in access to diagnostics and antimicrobials while incentivizing their appropriate use in low- and middle-income countries.

Key Points: 
  • The new coalition, the Antimicrobial Resistance Access and Stewardship Initiative (AMRASI), is a groundbreaking initiative that will use a sustainable, market-driven approach to address critical gaps in access to diagnostics and antimicrobials while incentivizing their appropriate use in low- and middle-income countries.
  • Following a series of convenings to align on these key pilot areas, the coalition aims to mobilize and launch the targeted pilot to test the model in up to two low- and middle-income countries.
  • GETF is serving as the AMRASI Secretariat, supporting the coalition to plan for pilot design in the first half of 2024.
  • "The AMRASI coalition provides a great opportunity to test innovative strategies to combat AMR and develop learnings that can be shared across the sector.